Strategic Financing Recent €10M+ funding indicates capacity to scale manufacturing and product development. Target BD discussions around capacity expansion, GMP upgrades, and new formulation programs to align with investor-backed growth.

Collaborative Programs Partnership with HMNC Brain Health on the Ketabon program suggests openness to co-development and joint ventures in high-need areas. Pitch co-development of fast-to-market formulations or extended-release projects with a focus on TRD and neuropharmacology.

Specialized Manufacturing Focus on difficult-to-make, innovative formulations positions the company for outsourcing complex fill-finish, formulation development, and small-batch production. Highlight capabilities for niche APIs, early-phase manufacturing, and scale-up services.

Regional Focus Based in Pratteln, Switzerland with a mid-sized team, there is potential for regional partnerships in Europe, regulatory consulting, and localized supply chain solutions to reduce time-to-market for European launches.

Technology Enablement Utilizes a diverse tech stack and analytics tools (MySQL, Jira, Google Analytics, ArcGIS, Office/365). Propose data-driven BD approaches, including supply chain transparency, quality metrics dashboards, and market/intelligence mapping for targeted outreach.